Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PNC129
MIFTS: 65

Pancreatic Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Pancreatic Adenocarcinoma

About this section

MalaCards integrated aliases for Pancreatic Adenocarcinoma:

Name: Pancreatic Adenocarcinoma 12 29 6 15 17
Adenocarcinoma of the Pancreas 12
Pancreas Adenocarcinoma 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4074
NCIt 50 C8294
SNOMED-CT 67 700423003
UMLS 71 C0281361
Sources

Summaries for Pancreatic Adenocarcinoma

About this section
Disease Ontology : 12 A pancreatic carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Pancreatic Adenocarcinoma, also known as adenocarcinoma of the pancreas, is related to pancreatic ductal adenocarcinoma and pancreatic cancer, and has symptoms including abdominal pain, pruritus and icterus. An important gene associated with Pancreatic Adenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and Gene Expression. The drugs Ethanol and Propofol have been mentioned in the context of this disorder. Affiliated tissues include pancreas, lymph node and endothelial, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Pancreatic Adenocarcinoma

About this section

Diseases related to Pancreatic Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 682)
# Related Disease Score Top Affiliating Genes
1 pancreatic ductal adenocarcinoma 32.8 VEGFA TP53 SMAD4 KRAS ERBB2 EGFR
2 pancreatic cancer 32.2 VEGFA TP53 SMAD4 PIK3CA MUC4 MAP2K2
3 adenocarcinoma 31.7 VEGFA TP53 SMAD4 POLE PIK3CA MUC4
4 exanthem 31.3 VEGFA KRAS HRAS ERBB2 EGFR
5 intrahepatic cholangiocarcinoma 31.2 TP53 SMAD4 MUC4 KRAS ERBB2 EGFR
6 pancreatic ductal carcinoma 31.1 VEGFA TP53 SMAD4 ERBB2 EGFR CDKN2A
7 cholangiocarcinoma 31.1 VEGFA TP53 SMAD4 PIK3CA MUC4 KRAS
8 mucinous adenocarcinoma 31.0 VEGFA TP53 KRAS ERBB2 EGFR CDKN2A
9 pancreas disease 31.0 U2AF1 TP53 KRAS HRAS
10 cystadenocarcinoma 30.9 VEGFA TP53 PIK3CA HRAS ERBB2
11 papilloma 30.9 VEGFA TP53 KRAS ERBB2 EGFR CDKN2A
12 in situ carcinoma 30.8 TP53 PIK3CA HRAS ERBB2 EGFR CTNNB1
13 gastrointestinal stromal tumor 30.8 VEGFA TP53 KRAS ERBB2 EGFR CDKN2A
14 bile duct cancer 30.8 VEGFA TP53 SMAD4 MUC4 KRAS HRAS
15 biliary tract cancer 30.8 SMAD4 MUC4 ERBB2 EGFR
16 acinar cell carcinoma 30.7 TP53 SMAD4 CTNNB1 BRCA2
17 cholecystitis 30.7 TP53 MUC4 EGFR CDKN2A
18 signet ring cell adenocarcinoma 30.7 TP53 KRAS HRAS ERBB2 CTNNB1
19 adenoma 30.7 TP53 SMAD4 PIK3CA KRAS GNAS CTNNB1
20 clear cell adenocarcinoma 30.7 TP53 SMAD4 PIK3CA
21 familial adenomatous polyposis 30.7 TP53 SMAD4 KRAS HRAS CTNNB1
22 appendix adenocarcinoma 30.7 KRAS HRAS GNAS
23 tubular adenocarcinoma 30.7 ERBB2 EGFR CTNNB1
24 adenosquamous carcinoma 30.7 TP53 SMAD4 PIK3CA MUC4 KRAS EGFR
25 colon adenoma 30.7 VEGFA SMAD4 RXRA KRAS CTNNB1
26 gallbladder disease 30.7 TP53 KRAS HRAS ERBB2 EGFR CTNNB1
27 peutz-jeghers syndrome 30.7 TP53 SMAD4 GNAS EGFR CTNNB1 BRCA2
28 hereditary breast ovarian cancer syndrome 30.7 TP53 KRAS HRAS ERBB2 CDKN2A BRCA2
29 hemangioma 30.7 VEGFA TP53 KRAS CTNNB1
30 serous cystadenocarcinoma 30.6 VEGFA TP53 PIK3CA KRAS HRAS ERBB2
31 colon adenocarcinoma 30.6 VEGFA TP53 SMAD4 PIK3CA KRAS ERBB2
32 esophageal cancer 30.6 VEGFA TP53 SMAD4 PIK3CA MUC4 KRAS
33 lynch syndrome 30.6 TP53 SMAD4 POLE PIK3CA KRAS HRAS
34 duodenum cancer 30.5 TP53 SMAD4 KRAS HRAS
35 adenocarcinoma in situ 30.5 U2AF1 KRAS CDKN2A
36 keratosis 30.5 TP53 PIK3CA HRAS CDKN2A
37 peripheral nervous system disease 30.5 VEGFA U2AF1 TP53 HRAS ERBB2 EGFR
38 cervical adenocarcinoma 30.5 TP53 KRAS ERBB2 EGFR CDKN2A
39 keratosis, seborrheic 30.5 TP53 PIK3CA CDKN2A
40 gastroesophageal junction adenocarcinoma 30.5 VEGFA ERBB2 EGFR
41 teratoma 30.5 TP53 KRAS CTNNB1 CDKN2A
42 biliary tract disease 30.5 TP53 KRAS HRAS CTNNB1
43 liposarcoma 30.5 TP53 PIK3CA CTNNB1 CDKN2A
44 sarcoma 30.5 VEGFA TP53 PIK3CA KRAS HRAS CTNNB1
45 transitional cell carcinoma 30.5 TP53 HRAS ERBB2 EGFR CDKN2A
46 pseudomyxoma peritonei 30.5 TP53 KRAS GNAS CTNNB1
47 papillary adenocarcinoma 30.5 TP53 ERBB2 BRCA2
48 mantle cell lymphoma 30.4 VEGFA TP53 PIK3CA CTNNB1 CDKN2A
49 kidney cancer 30.4 VEGFA TP53 PIK3CA EGFR CDKN2A
50 gallbladder cancer 30.4 TP53 PIK3CA KRAS ERBB2 EGFR CTNNB1

Graphical network of the top 20 diseases related to Pancreatic Adenocarcinoma:



Diseases related to Pancreatic Adenocarcinoma
Sources

Symptoms & Phenotypes for Pancreatic Adenocarcinoma

About this section

UMLS symptoms related to Pancreatic Adenocarcinoma:


abdominal pain, pruritus, icterus

GenomeRNAi Phenotypes related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.57 EGFR HRAS KRAS PIK3CA
2 Decreased viability GR00055-A-2 10.57 EGFR HRAS KRAS PIK3CA
3 Decreased viability GR00055-A-3 10.57 KRAS
4 Decreased viability GR00106-A-0 10.57 KRAS
5 Decreased viability GR00221-A-1 10.57 EGFR HRAS KRAS PIK3CA CDKN2A RXRA
6 Decreased viability GR00221-A-2 10.57 HRAS KRAS PIK3CA
7 Decreased viability GR00221-A-3 10.57 HRAS CDKN2A
8 Decreased viability GR00221-A-4 10.57 EGFR PIK3CA CDKN2A
9 Decreased viability GR00249-S 10.57 RXRA
10 Decreased viability GR00301-A 10.57 KRAS
11 Decreased viability GR00381-A-1 10.57 KRAS RXRA
12 Decreased viability GR00402-S-2 10.57 PIK3CA
13 Decreased cell migration GR00055-A-1 9.8 MAP2K2
14 Decreased cell migration GR00055-A-3 9.8 EGFR HRAS PIK3CA
15 Reduced mammosphere formation GR00396-S 9.17 EGFR GNAS HRAS KRAS POLE RXRA
16 Increased focal adhesion (FA) area, decreased number of small and round FAs, increased peripheral FA formation, increased cell spreading GR00210-A 8.65 CTNNB1

MGI Mouse Phenotypes related to Pancreatic Adenocarcinoma:

46 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.46 CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
2 cellular MP:0005384 10.46 BRCA2 CDKN2A CTNNB1 EGFR ERBB2 GNAS
3 growth/size/body region MP:0005378 10.45 BRCA2 CDKN2A CTNNB1 EGFR ERBB2 GNAS
4 behavior/neurological MP:0005386 10.44 BRCA2 CDKN2A CTNNB1 ERBB2 GNAS HRAS
5 endocrine/exocrine gland MP:0005379 10.43 BRCA2 CDKN2A CTNNB1 EGFR ERBB2 GNAS
6 integument MP:0010771 10.41 BRCA2 CDKN2A CTNNB1 EGFR ERBB2 GNAS
7 homeostasis/metabolism MP:0005376 10.4 BRCA2 CDKN2A CTNNB1 EGFR ERBB2 GNAS
8 mortality/aging MP:0010768 10.4 BRCA2 CDKN2A CTNNB1 EGFR ERBB2 GNAS
9 craniofacial MP:0005382 10.38 CTNNB1 EGFR ERBB2 GNAS HRAS KRAS
10 digestive/alimentary MP:0005381 10.38 BRCA2 CDKN2A CTNNB1 EGFR ERBB2 HRAS
11 embryo MP:0005380 10.37 BRCA2 CDKN2A CTNNB1 EGFR ERBB2 KRAS
12 immune system MP:0005387 10.33 BRCA2 CDKN2A CTNNB1 EGFR GNAS KRAS
13 neoplasm MP:0002006 10.33 BRCA2 CDKN2A CTNNB1 EGFR ERBB2 GNAS
14 nervous system MP:0003631 10.28 BRCA2 CDKN2A CTNNB1 EGFR ERBB2 GNAS
15 limbs/digits/tail MP:0005371 10.26 BRCA2 CTNNB1 EGFR ERBB2 GNAS KRAS
16 muscle MP:0005369 10.26 CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
17 normal MP:0002873 10.18 BRCA2 CTNNB1 EGFR ERBB2 GNAS HRAS
18 liver/biliary system MP:0005370 10.16 CDKN2A CTNNB1 EGFR GNAS KRAS RXRA
19 hearing/vestibular/ear MP:0005377 10.11 CTNNB1 EGFR GNAS KRAS MAP2K2 RXRA
20 no phenotypic analysis MP:0003012 10.06 CDKN2A CTNNB1 EGFR GNAS HRAS KRAS
21 renal/urinary system MP:0005367 9.91 CTNNB1 EGFR GNAS HRAS KRAS RXRA
22 reproductive system MP:0005389 9.9 BRCA2 CDKN2A CTNNB1 EGFR ERBB2 KRAS
23 pigmentation MP:0001186 9.8 CDKN2A CTNNB1 EGFR KRAS RXRA TP53
24 respiratory system MP:0005388 9.65 CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
25 skeleton MP:0005390 9.5 BRCA2 CDKN2A CTNNB1 EGFR ERBB2 GNAS
Sources

Drugs & Therapeutics for Pancreatic Adenocarcinoma

About this section

Drugs for Pancreatic Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 276)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4 64-17-5 702
2
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
3
Desflurane Approved Phase 4 57041-67-5 42113
4 Anesthetics Phase 4
5 Anesthetics, Inhalation Phase 4
6 Anesthetics, General Phase 4
7
Docetaxel Approved, Investigational Phase 2, Phase 3 114977-28-5 148124
8
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
9
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
10
Darbepoetin alfa Approved, Investigational Phase 2, Phase 3 209810-58-2, 11096-26-7
11
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 6857599 43805
12
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
13
tannic acid Approved Phase 3 1401-55-4
14
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2 149436
15
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
16
leucovorin Approved Phase 2, Phase 3 58-05-9 6006
17
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
18
Irinotecan Approved, Investigational Phase 2, Phase 3 97682-44-5, 100286-90-6 60838
19
Capecitabine Approved, Investigational Phase 2, Phase 3 154361-50-9 60953
20
Gemcitabine Approved Phase 3 95058-81-4 60750
21
Heparin Approved, Investigational Phase 3 9005-49-6 772 9812414
22
Dalteparin Approved Phase 3 9005-49-6
23
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
24
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
25
Asparagine Approved, Investigational, Nutraceutical Phase 3 70-47-3 6267
26
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
27
Rubitecan Investigational Phase 3 91421-42-0
28
Irofulven Investigational Phase 3 158440-71-2
29 ON 01910 Phase 3
30 Folfirinox Phase 3
31 Hematinics Phase 3
32
asparaginase Phase 3
33 Vitamin B9 Phase 2, Phase 3
34 Folate Phase 2, Phase 3
35 Liver Extracts Phase 2, Phase 3
36 Immunosuppressive Agents Phase 2, Phase 3
37 Albumin-Bound Paclitaxel Phase 2, Phase 3
38 Tubulin Modulators Phase 2, Phase 3
39 Antimitotic Agents Phase 2, Phase 3
40 Protective Agents Phase 2, Phase 3
41 Micronutrients Phase 2, Phase 3
42 Trace Elements Phase 2, Phase 3
43 Vitamin B Complex Phase 2, Phase 3
44 Vitamins Phase 2, Phase 3
45 Nutrients Phase 2, Phase 3
46 Antidotes Phase 2, Phase 3
47 Immunologic Factors Phase 3
48 Antimetabolites Phase 3
49 Antiviral Agents Phase 3
50 Fibrinolytic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 663)
# Name Status NCT ID Phase Drugs
1 The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer Unknown status NCT03401827 Phase 4 Chemotherapy (Gemcitabine + nab-paclitaxel)
2 A Pharmacokinetic Study of Adjuvant Capecitabine in Patients Who Have Undergone Proximal Pancreatico-duodenectomy for Resection of Pancreatic Adenocarcinoma Completed NCT00854477 Phase 4 capecitabine
3 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN) With Alcohol in Patients With Locally Advanced and Unresectable Pancreatic Adenocarcinoma: A Randomized Pilot Study Completed NCT00578279 Phase 4 dehydrated alcohol
4 Resectable Pancreatic Adenocarcinoma - Does the Type of Anesthesia Have an Impact on Circulating Tumor Cells? Completed NCT02335151 Phase 4 Desflurane
5 A Dose Escalation Safety Study of Locally-Delivered (Intra-Arterial) Gemcitabine in Unresectable Adenocarcinoma of the Pancreas Active, not recruiting NCT02237157 Phase 4 Gemcitabine, local delivery
6 Exocrine Pancreatic Insufficiency in Pancreatic Cancer: Evaluating the Need and Efficacy of Pancreatic Enzyme Replacement Therapy Withdrawn NCT01401387 Phase 4
7 A Pilot Study of Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma Withdrawn NCT03891979 Phase 4 Pembrolizumab;Ciprofloxacin 500mg PO BID days 1-29;Metronidazole 500mg PO TID days 1-29
8 Phase III Randomized, Double-blind Study Comparing Gemcitabine and Sorafenib or a Placebo in Patients With Locally Advanced or Metastatic Cancer of the Pancreas. Unknown status NCT00541021 Phase 3 gemcitabine hydrochloride;sorafenib tosylate
9 Phase III Randomized Study Of Gemcitabine Versus Gemcitabine-Oxaliplatine In Patients With Locally Advanced Or Metastatic Pancreatic Carcinoma Unknown status NCT00075452 Phase 3 gemcitabine hydrochloride;oxaliplatin
10 Phase II Randomisee Dans Les Adenocarcinomes Metastatiques Du Pancreas: Gemox Et Gemox Simplifie. [GEMOX] Unknown status NCT00268411 Phase 3 gemcitabine hydrochloride;oxaliplatin
11 Randomized Phase II/III Trial Comparing Folririnox Association [Oxaliplatin / Irinotecan / LV5FU2] Versus Gemcitabine in First Line of Chemotherapy in Metastatics Pancreas Cancers Patients Unknown status NCT00112658 Phase 2, Phase 3 fluorouracil;gemcitabine hydrochloride;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
12 Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) Versus 5-Fluorouracil (5-FU) in Pancreatic Cancer Patients That Have Progressive Disease Following Gemcitabine HCl Treatment Unknown status NCT00005871 Phase 3 fluorouracil;rubitecan
13 Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) Versus Gemcitabine HCl in Chemonaive Pancreatic Cancer Patients Unknown status NCT00005869 Phase 3 gemcitabine hydrochloride;rubitecan
14 Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) Versus Most Appropriate Therapy in Refractory Pancreatic Cancer Patients Unknown status NCT00005870 Phase 3 fluorouracil;gemcitabine hydrochloride;mitomycin C;rubitecan
15 A Phase III Randomized, Controlled Study to Evaluate the Safety and Efficacy of PANVACâ„¢-VF in Combination With GM-CSF Versus Best Supportive Care or Palliative Chemotherapy in Patients With Metastatic (Stage IV) Adenocarcinoma of the Pancreas Who Have Failed a Gemcitabine-Containing Chemotherapy Regimen Unknown status NCT00088660 Phase 3
16 Use of the Eus-guided Cryothermal Ablation in the Multimodality Approach to Patients With Stage III (Locally Advanced and Borderline Resectable) Pancreatic Adenocarcinoma Unknown status NCT03649035 Phase 3
17 Phase II Study: Neoadjuvant Gemcitabine, Docetaxel and Capecitabine Followed by Neoadjuvant Radiation Therapy With Gemcitabine and Capecitabine in the Treatment of Stage II and III Pancreatic Adenocarcinoma Unknown status NCT01065870 Phase 2, Phase 3 Neoadjuvant gemcitabine, capecitabine, and docetaxel;Gemcitabine, capecitabine, docetaxel followed by radiotherapy
18 A Phase III Study of Pre and Post Chemoradiation 5-FU vs. Pre and Post Chemoradiation Gemcitabine for Postoperative Adjuvant Treatment of Resected Pancreatic Adenocarcinoma Completed NCT00003216 Phase 3 fluorouracil;gemcitabine hydrochloride
19 Randomized Phase II-III Trial of Post-operative Treatment of Pancreatic Adenocarcinoma: Gemcitabine Versus PEFG Followed by Radiochemotherapy With Concomitant Continuous Infusion of 5-fluorouracil Completed NCT00960284 Phase 2, Phase 3 capecitabine;cisplatin;epirubicin hydrochloride;fluorouracil;gemcitabine hydrochloride
20 Non Resectable But Non Metastatic Adenocarcinoma of the Exocrine Pancreas Non Resecables. Randomised Phase III: Initial Radiochimiotherapy (5-FU, Cisplatine, 60 GY Radiotherapy) Followed by Gemcitabine Versus Gemcitabine Alone Completed NCT00416507 Phase 3 fluorouracil;gemcitabine hydrochloride;liposomal cisplatin
21 Essai Randomise Comparant Deux Stategies De Chimiotherapie Dans Les Cancers Pancreatiques Avances: LV5FU2 Simplifie + Cisplatine Suivi de Gemcitabine, Versus Gemcitabine Suivi de LV5FU2 Simplifie + Cisplatine en Can de Progression Completed NCT00303758 Phase 3 cisplatin;fluorouracil;gemcitabine hydrochloride;leucovorin calcium
22 Randomized Phase II/III Study Comparing Gemcitabine Followed by Gemcitabine Plus Concomitant Radiation (50.4 Gy) Versus Control After Curative Pancreaticoduodenectomy for Pancreatic Head Cancer Completed NCT00064207 Phase 2, Phase 3 gemcitabine hydrochloride
23 A Phase III, Randomized Study of Gemcitabine (Fixed-Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus Gemcitabine (Fixed-Dose Rate Infusion) Versus Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma Completed NCT00058149 Phase 3 gemcitabine hydrochloride;oxaliplatin
24 A Randomized Phase III Study Of Gemcitabine In Combination With Radiation Therapy Versus Gemcitabine Alone In Patients With Localized, Unresectable Pancreatic Cancer Completed NCT00057876 Phase 3 Gemcitabine
25 A Randomized Placebo Controlled Study Of OSI-774 (TARCEVA) Plus Gemcitabine In Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer Completed NCT00026338 Phase 3 erlotinib hydrochloride;gemcitabine hydrochloride
26 An Open Label, Randomized, Controlled, Phase III, Multi-center, Clinical Trial Of PN401 With High Dose 5-Fluorouracil (5FU) Versus Gemcitabine For Treatment Of Patients With Advanced Pancreatic Cancer Completed NCT00024427 Phase 3 fluorouracil;gemcitabine hydrochloride;triacetyluridine
27 A Prospective, Randomized Trial of Extended Lymphadenectomy in the Management of Resectable Pancreatic Cancer Completed NCT00003049 Phase 3 fluorouracil;leucovorin calcium
28 A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer Completed NCT00075686 Phase 3 gemcitabine hydrochloride
29 Gemcitabine Plus Capecitabine Versus Gemcitabine Alone In Advanced Pancreatic Cancer. A Randomized Phase III Trial Completed NCT00030732 Phase 3 Gemcitabine + Capecitabine;Gemcitabine alone
30 Infusional 5-Fluorouracil With or Without Cisplatin and With or Without Chronomodulation Against Locally-Advanced or Metastatic Pancreatic Cancer. A Multicenter Randomized Phase III Trial. Completed NCT00003029 Phase 3 cisplatin;fluorouracil
31 Randomized Multicenter Phase III Study in Patients With Locally Advanced Adenocarcinoma of the Pancreas: Gemcitabine With or Without Chemoradiotherapy and With or Without Erlotinib. Intergroup Study Completed NCT00634725 Phase 3 capecitabine;erlotinib hydrochloride;gemcitabine hydrochloride
32 A Randomized Phase III Trial Of Gemcitabine Plus Bevacizumab (NSC#704865 IND#7621) Versus Gemcitabine Plus Placebo In Patients With Advanced Pancreatic Cancer Completed NCT00088894 Phase 3 gemcitabine hydrochloride
33 Prospective, Randomized, Controlled, Double-Blind, Multi-National, Multi-Center Study of G17DT Immunogen in Combination With Gemcitabine Versus Placebo in Combination With Gemcitabine in Previously Untreated Subjects With Locally Advanced (Nonresectable Stage II and III), Recurrent Disease Following Primary Resection, or Metastatic (Stage IV) Adenocarcinoma of the Pancreas (Protocol No. PC4) Completed NCT00044031 Phase 3
34 A Randomized Phase III Study of Weekly ABI-007 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Adenocarcinoma of the Pancreas Completed NCT00844649 Phase 3 Albumin-bound paclitaxel (ABI-007);Gemcitabine
35 A Phase III, Multi-center, Randomized, Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combined With Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Cancer Completed NCT01360853 Phase 3 ON 01910.Na;Gemcitabine;Gemcitabine
36 A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Completed NCT01746979 Phase 3 TH-302;Gemcitabine;Placebo (5 percent dextrose - D5W)
37 A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma Completed NCT02436668 Phase 3 Ibrutinib;Gemcitabine;Nab-paclitaxel
38 Phase III Trial Of Irofulven Vs. 5-Fluorouracil In Patients With Gemcitabine-Refractory Advanced Pancreatic Adenocarcinoma Completed NCT00033735 Phase 3 fluorouracil;Irofulven
39 A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine Completed NCT00099294 Phase 3 Glufosfamide
40 A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Completed NCT02993731 Phase 3 Napabucasin;Nab-paclitaxel;Gemcitabine
41 Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma. Recruiting NCT02072616 Phase 3
42 Phase II/III of Randomized Controlled Clinical Research on Irreversible Electroporation Synchronous Chemotherapy for Locally Advanced Pancreatic Adenocarcinoma Recruiting NCT03673137 Phase 2, Phase 3 Gemcitabine
43 Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma Recruiting NCT03377491 Phase 3 Gemcitabine;nab paclitaxel
44 An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas Recruiting NCT04083235 Phase 3 Irinotecan Liposomal Injection;Oxaliplatin;5Fluorouracil;Leucovorin;Nab-paclitaxel;Gemcitabine
45 A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment Recruiting NCT03126435 Phase 3 EndoTAG-1;Gemcitabine
46 A Randomized Two-armed Open Study on the Adjuvant Therapy in Patients With R0/R1 Resected Pancreatic Carcinoma With Gemcitabine Plus Capecitabine (Arm GC) vs. Gemcitabine Plus Cisplatin With Regional Hyperthermia (Arm GPH) Recruiting NCT01077427 Phase 3 Gemcitabine + Capecitabine
47 A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Fluorouracil (5-FU) in Patients With Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine Recruiting NCT01954992 Phase 3 Glufosfamide;Fluorouracil
48 Intrabdominal Hyperthermic Chemotherapy Using Gemcitabine to Treat Pancreatic Carcinomatosis Recruiting NCT03251365 Phase 2, Phase 3 HIPEC-gemcitabine
49 A Phase III Randomized Study Evaluating Gemcitabine and Paclitaxel Versus Gemcitabine Alone After FOLFIRINOX Failure or Intolerance in Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT03943667 Phase 3 Gemcitabine;Paclitaxel
50 Randomized Phase 3 Trial Comparing FOLFOX to Gemcitabine in Metastatic First-line in Patients With Pancreatic Adenocarcinoma and Non-fit for FOLFIRINOX Recruiting NCT04167007 Phase 3 Gemcitabine;FOLFOX

Search NIH Clinical Center for Pancreatic Adenocarcinoma

Sources

Genetic Tests for Pancreatic Adenocarcinoma

About this section

Genetic tests related to Pancreatic Adenocarcinoma:

# Genetic test Affiliating Genes
1 Pancreatic Adenocarcinoma 29
Sources

Anatomical Context for Pancreatic Adenocarcinoma

About this section

MalaCards organs/tissues related to Pancreatic Adenocarcinoma:

40
Pancreas, Lymph Node, Endothelial, T Cells, Liver, Colon, Neutrophil
Sources

Publications for Pancreatic Adenocarcinoma

About this section

Articles related to Pancreatic Adenocarcinoma:

(show top 50) (show all 7437)
# Title Authors PMID Year
1
Downregulation of long non-coding RNA LINC00460 inhibits the proliferation, migration and invasion, and promotes apoptosis of pancreatic cancer cells via modulation of the miR-320b/ARF1 axis. 61
33345740 2021
2
Myelodysplastic Syndrome in Patients with Gastro-Pancreatic Malignancies: A Case Series and Review of Literature. 61
32685937 2021
3
Controversial Role of Adjuvant Therapy in Node-Negative Invasive Intraductal Papillary Mucinous Neoplasm. 61
32743713 2021
4
ASO Author Reflections: Tumor Biology and Safe Surgery Remain Major Determinants of Survival After Resection of Pancreatic Adenocarcinoma. 61
32880772 2021
5
Exploring the significance of novel immune-related gene signatures in the prognosis and immune features of pancreatic adenocarcinoma. 61
33465729 2021
6
Pancreatic adenocarcinoma: molecular drivers and the role of targeted therapy. 61
33398620 2021
7
Side-by-side comparison of next-generation sequencing, cytology, and histology in diagnosing locally advanced pancreatic adenocarcinoma. 61
32640200 2021
8
Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience. 61
30946073 2021
9
Chemoradiotherapy after curative surgery for locally advanced pancreatic cancer: A 20-year single center experience. 61
33285435 2021
10
Leptomeningeal disease in pancreas ductal adenocarcinoma: A manifestation of longevity. 61
33582005 2021
11
A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. 61
33188873 2021
12
Racial Disparity in Pancreatoduodenectomy for Borderline Resectable Pancreatic Adenocarcinoma. 61
32651695 2021
13
CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy. 61
32845389 2021
14
Classic adrenal adenoma undergoing necrosis secondary to chemotherapy for pancreatic adenocarcinoma. 61
33595187 2021
15
CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma. 61
33271264 2021
16
Identification of novel candidate biomarkers for pancreatic adenocarcinoma based on TCGA cohort. 61
33591944 2021
17
DUODENAL LYMPHANGIECTASIAS - THE FIRST SIGN OF PANCREATIC ADENOCARCINOMA. 61
33569966 2021
18
Circulating tumor DNA (ctDNA) based testing and actionable findings in patients with advanced and metastatic pancreatic adenocarcinoma. 61
33555095 2021
19
Targeting B Cells in Pancreatic Adenocarcinoma: Does RESOLVE resolve the question? 61
33607222 2021
20
Forecasting sensitive targets of the kynurenine pathway in pancreatic adenocarcinoma using mathematical modeling. 61
33523522 2021
21
C1GALT1 high expression is associated with poor survival of patients with pancreatic ductal adenocarcinoma and promotes cell invasiveness through integrin αv. 61
33420364 2021
22
A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma. 61
33593311 2021
23
Neoadjuvant Checkpoint Blockade in Lynch Syndrome-Related Pancreatic Adenocarcinoma. 61
33565809 2021
24
Development and clinical validation of a novel 9-gene prognostic model based on multi-omics in pancreatic adenocarcinoma. 61
33316381 2021
25
[Primary pancreatic adenocarcinoma with enteroblastic differentiation: report of a case]. 61
33535315 2021
26
TFAP2A-induced SLC2A1-AS1 promotes cancer cell proliferation. 61
33580997 2021
27
Idiopathic acute pancreatitis-A myth or reality? Role of endoscopic ultrasonography and magnetic resonance cholangiopancreatography in its diagnosis. 61
33548019 2021
28
Ibrutinib in Combination with Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients with Metastatic Pancreatic Adenocarcinoma: Phase 3 RESOLVE Study. 61
33539945 2021
29
Robotic Pancreaticoduodenectomy for a Technically Challenging Pancreatic Head Cancer. 61
33565012 2021
30
Collision of a pancreatic ductal adenocarcinoma and a pancreatic neuroendocrine tumor associated with multiple endocrine neoplasm type 1. 61
32951175 2021
31
B3GNT3: A prognostic biomarker associated with immune cell infiltration in pancreatic adenocarcinoma. 61
33552277 2021
32
α1,6-Fucosyltransferase contributes to cell migration and proliferation as well as to cancer stemness features in pancreatic carcinoma. 61
33571582 2021
33
Fam83D promotes tumorigenesis and gemcitabine resistance of pancreatic adenocarcinoma through the Wnt/β-catenin pathway. 61
33571515 2021
34
An Angiopep2-PAPTP Construct Overcomes the Blood-Brain Barrier. New Perspectives against Brain Tumors. 61
33562146 2021
35
HOX transcript antisense RNA: An oncogenic lncRNA in diverse malignancies. 61
33238156 2021
36
Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1). 61
33405269 2021
37
Distal Pancreatectomy with Celiac Axis Resection (Modified Appleby Procedure) and Arterial Reconstruction for Locally Advanced Pancreatic Adenocarcinoma After FOLFIRINOX Chemotherapy and Chemoradiation Therapy. 61
32588265 2021
38
Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis. 61
33607382 2021
39
Association between fasting blood glucose levels at admission and overall survival of patients with pancreatic cancer. 61
33549043 2021
40
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. 61
33338442 2021
41
Bioinformatics analysis reveals TSPAN1 as a candidate biomarker of progression and prognosis in pancreatic cancer. 61
33188589 2021
42
A Phase 1 Dose Escalation Study of Neoadjuvant SBRT Plus Elective Nodal Radiation with Concurrent Capecitabine for Resectable Pancreatic Cancer. 61
32942002 2021
43
Depression preceding the diagnosis of pancreatic cancer. 61
33542022 2021
44
Immune Stimulating Antibody-Photosensitizer Conjugates via Fc-Mediated Dendritic Cell Phagocytosis and Phototriggered Immunogenic Cell Death for KRAS-Mutated Pancreatic Cancer Treatment. 61
33590726 2021
45
SETD8 potentiates constitutive ERK1/2 activation via epigenetically silencing DUSP10 expression in pancreatic cancer. 61
33232789 2021
46
Von Hippel-Lindau syndrome with pancreatic adenocarcinoma (with videos). 61
33586693 2021
47
Pancreatic adenocarcinoma presenting as subacute cutaneous lupus, tripe palms and acanthosis nigricans maligna. 61
32696454 2021
48
Identification of glycolysis related pathways in pancreatic adenocarcinoma and liver hepatocellular carcinoma based on TCGA and GEO datasets. 61
33607990 2021
49
Real-world patterns of adjuvant chemotherapy treatment for patients with resected pancreatic adenocarcinoma. 61
33534008 2021
50
Erratum: MicroRNA-183-5p promotes the proliferation, invasion and metastasis of human pancreatic adenocarcinoma cells. 61
33456544 2021
Sources

Variations for Pancreatic Adenocarcinoma

About this section

ClinVar genetic disease variations for Pancreatic Adenocarcinoma:

6 (show top 50) (show all 436)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_000546.6(TP53):c.523C>T (p.Arg175Cys) SNV Likely pathogenic 245851 rs138729528 17:7578407-7578407 17:7675089-7675089
2 POLE NM_006231.3(POLE):c.857C>A (p.Pro286His) SNV Likely pathogenic 376502 rs1057519943 12:133253184-133253184 12:132676598-132676598
3 TP53 NM_000546.5(TP53):c.832C>G (p.Pro278Ala) SNV Likely pathogenic 376645 rs17849781 17:7577106-7577106 17:7673788-7673788
4 CTNNB1 NM_001904.4(CTNNB1):c.97T>A (p.Ser33Thr) SNV Likely pathogenic 376393 rs1057519886 3:41266100-41266100 3:41224609-41224609
5 PIK3CA NM_006218.4(PIK3CA):c.3128T>C (p.Met1043Thr) SNV Likely pathogenic 376486 rs1057519937 3:178952073-178952073 3:179234285-179234285
6 TP53 NM_000546.5(TP53):c.742C>G (p.Arg248Gly) SNV Likely pathogenic 376652 rs121912651 17:7577539-7577539 17:7674221-7674221
7 TP53 NM_000546.5(TP53):c.518T>G (p.Val173Gly) SNV Likely pathogenic 376016 rs1057519747 17:7578412-7578412 17:7675094-7675094
8 TP53 NM_000546.5(TP53):c.818G>T (p.Arg273Leu) SNV Likely pathogenic 376655 rs28934576 17:7577120-7577120 17:7673802-7673802
9 POLE NM_006231.3(POLE):c.856C>T (p.Pro286Ser) SNV Likely pathogenic 376501 rs1057519944 12:133253185-133253185 12:132676599-132676599
10 TP53 NM_000546.5(TP53):c.706T>G (p.Tyr236Asp) SNV Likely pathogenic 142183 rs587782289 17:7577575-7577575 17:7674257-7674257
11 TP53 NM_000546.5(TP53):c.422G>A (p.Cys141Tyr) SNV Likely pathogenic 140801 rs587781288 17:7578508-7578508 17:7675190-7675190
12 TP53 NM_000546.5(TP53):c.536A>T (p.His179Leu) SNV Likely pathogenic 376608 rs1057519991 17:7578394-7578394 17:7675076-7675076
13 RXRA NM_002957.6(RXRA):c.1280C>A (p.Ser427Tyr) SNV Likely pathogenic 376529 rs1057519958 9:137328351-137328351 9:134436505-134436505
14 HRAS NM_005343.4(HRAS):c.182A>C (p.Gln61Pro) SNV Likely pathogenic 376322 rs121913233 11:533874-533874 11:533874-533874
15 TP53 NM_000546.5(TP53):c.613T>G (p.Tyr205Asp) SNV Likely pathogenic 376686 rs1057520008 17:7578236-7578236 17:7674918-7674918
16 TP53 NM_000546.5(TP53):c.856G>A (p.Glu286Lys) SNV Likely pathogenic 183752 rs786201059 17:7577082-7577082 17:7673764-7673764
17 TP53 NM_000546.5(TP53):c.613T>C (p.Tyr205His) SNV Likely pathogenic 376685 rs1057520008 17:7578236-7578236 17:7674918-7674918
18 TP53 NM_000546.5(TP53):c.818G>C (p.Arg273Pro) SNV Likely pathogenic 231060 rs28934576 17:7577120-7577120 17:7673802-7673802
19 TP53 NM_000546.6(TP53):c.820G>T SNV Likely pathogenic 376674 rs1057520005 17:7577118-7577118 17:7673800-7673800
20 PIK3CA NM_006218.4(PIK3CA):c.3127A>T (p.Met1043Leu) SNV Likely pathogenic 376487 rs1057519936 3:178952072-178952072 3:179234284-179234284
21 TP53 NM_000546.5(TP53):c.404G>A (p.Cys135Tyr) SNV Likely pathogenic 141762 rs587781991 17:7578526-7578526 17:7675208-7675208
22 TP53 NM_000546.5(TP53):c.452C>A (p.Pro151His) SNV Likely pathogenic 376639 rs1057520000 17:7578478-7578478 17:7675160-7675160
23 TP53 NM_000546.5(TP53):c.833C>A (p.Pro278His) SNV Likely pathogenic 376646 rs876659802 17:7577105-7577105 17:7673787-7673787
24 TP53 NM_000546.5(TP53):c.405C>G (p.Cys135Trp) SNV Likely pathogenic 376561 rs1057519976 17:7578525-7578525 17:7675207-7675207
25 TP53 NM_000546.5(TP53):c.577C>A (p.His193Asn) SNV Likely pathogenic 376614 rs876658468 17:7578272-7578272 17:7674954-7674954
26 TP53 NM_000546.5(TP53):c.824G>T (p.Cys275Phe) SNV Likely pathogenic 376582 rs863224451 17:7577114-7577114 17:7673796-7673796
27 TP53 NM_000546.5(TP53):c.821T>G (p.Val274Gly) SNV Likely pathogenic 376676 rs1057520006 17:7577117-7577117 17:7673799-7673799
28 TP53 NM_000546.5(TP53):c.577C>T (p.His193Tyr) SNV Likely pathogenic 230256 rs876658468 17:7578272-7578272 17:7674954-7674954
29 TP53 NM_000546.5(TP53):c.734G>A (p.Gly245Asp) SNV Likely pathogenic 12355 rs121912656 17:7577547-7577547 17:7674229-7674229
30 TP53 NM_000546.5(TP53):c.644G>A (p.Ser215Asn) SNV Likely pathogenic 376662 rs587782177 17:7578205-7578205 17:7674887-7674887
31 TP53 NM_000546.5(TP53):c.536A>C (p.His179Pro) SNV Likely pathogenic 376611 rs1057519991 17:7578394-7578394 17:7675076-7675076
32 CTNNB1 NM_001904.4(CTNNB1):c.121A>G (p.Thr41Ala) SNV Likely pathogenic 17580 rs121913412 3:41266124-41266124 3:41224633-41224633
33 TP53 NM_000546.5(TP53):c.815T>A (p.Val272Glu) SNV Likely pathogenic 376673 rs876660333 17:7577123-7577123 17:7673805-7673805
34 TP53 NM_000546.5(TP53):c.487T>A (p.Tyr163Asn) SNV Likely pathogenic 376679 rs786203436 17:7578443-7578443 17:7675125-7675125
35 TP53 NM_000546.5(TP53):c.820G>C (p.Val274Leu) SNV Likely pathogenic 376678 rs1057520005 17:7577118-7577118 17:7673800-7673800
36 TP53 NM_000546.5(TP53):c.844C>G (p.Arg282Gly) SNV Likely pathogenic 140821 rs28934574 17:7577094-7577094 17:7673776-7673776
37 TP53 NM_000546.5(TP53):c.734G>C (p.Gly245Ala) SNV Likely pathogenic 265357 rs121912656 17:7577547-7577547 17:7674229-7674229
38 HRAS NM_005343.4(HRAS):c.181C>G (p.Gln61Glu) SNV Likely pathogenic 376444 rs28933406 11:533875-533875 11:533875-533875
39 TP53 NM_000546.5(TP53):c.764T>G (p.Ile255Ser) SNV Likely pathogenic 376622 rs876659675 17:7577517-7577517 17:7674199-7674199
40 TP53 NM_000546.5(TP53):c.641A>T (p.His214Leu) SNV Likely pathogenic 376616 rs1057519992 17:7578208-7578208 17:7674890-7674890
41 TP53 NM_000546.5(TP53):c.824G>A (p.Cys275Tyr) SNV Likely pathogenic 215997 rs863224451 17:7577114-7577114 17:7673796-7673796
42 PIK3CA NM_006218.4(PIK3CA):c.3127A>G (p.Met1043Val) SNV Likely pathogenic 376485 rs1057519936 3:178952072-178952072 3:179234284-179234284
43 MAP2K2 NM_030662.3(MAP2K2):c.169T>G (p.Phe57Val) SNV Likely pathogenic 8273 rs121434498 19:4117551-4117551 19:4117553-4117553
44 CTNNB1 NM_001904.4(CTNNB1):c.98C>T (p.Ser33Phe) SNV Likely pathogenic 17583 rs121913400 3:41266101-41266101 3:41224610-41224610
45 TP53 NM_000546.5(TP53):c.659A>C (p.Tyr220Ser) SNV Likely pathogenic 12383 rs121912666 17:7578190-7578190 17:7674872-7674872
46 TP53 NM_000546.5(TP53):c.814G>A (p.Val272Met) SNV Likely pathogenic 185814 rs121912657 17:7577124-7577124 17:7673806-7673806
47 TP53 NM_000546.5(TP53):c.743G>T (p.Arg248Leu) SNV Likely pathogenic 230253 rs11540652 17:7577538-7577538 17:7674220-7674220
48 TP53 NM_000546.5(TP53):c.841G>T (p.Asp281Tyr) SNV Likely pathogenic 376585 rs764146326 17:7577097-7577097 17:7673779-7673779
49 TP53 NM_000546.5(TP53):c.857A>T (p.Glu286Val) SNV Likely pathogenic 376592 rs1057519985 17:7577081-7577081 17:7673763-7673763
50 CTNNB1 NM_001904.4(CTNNB1):c.98C>A (p.Ser33Tyr) SNV Likely pathogenic 17577 rs121913400 3:41266101-41266101 3:41224610-41224610
Sources

Expression for Pancreatic Adenocarcinoma

About this section
Search GEO for disease gene expression data for Pancreatic Adenocarcinoma.
Sources

Pathways for Pancreatic Adenocarcinoma

About this section

Pathways related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 142)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 63
Show member pathways
 13.96 VEGFA TP53 SMAD4 MAP2K2 KRAS HRAS
2
Gene Expression 65
Show member pathways
 13.93 VEGFA U2AF1 TP53 SMAD4 SF3B2 RXRA
3
HIV Life Cycle 65
Show member pathways
 13.83 SMAD4 PIK3CA MUC4 MAP2K2 KRAS HRAS
4
GPCR Pathway 63
Show member pathways
 13.83 VEGFA TP53 SMAD4 MAP2K2 KRAS HRAS
5
PEDF Induced Signaling 63
Show member pathways
 13.79 TP53 SMAD4 RXRA MAP2K2 KRAS HRAS
6
TGF-Beta Pathway 63
Show member pathways
 13.68 VEGFA TP53 SMAD4 PIK3CA MAP2K2 KRAS
7
Activation of cAMP-Dependent PKA 63
Show member pathways
 13.66 SMAD4 MAP2K2 KRAS HRAS GNAS ERBB2
8
Developmental Biology 65
Show member pathways
 13.62 VEGFA SMAD4 RXRA PIK3CA MED12 MAP2K2
9
Integrin Pathway 63
Show member pathways
 13.53 VEGFA PIK3CA MAP2K2 KRAS HRAS GNAS
10
Cytokine Signaling in Immune system 65
Show member pathways
 13.49 VEGFA TP53 PIK3CA MAP2K2 KRAS HRAS
11
Nanog in Mammalian ESC Pluripotency 63
Show member pathways
 13.42 VEGFA MAP2K2 KRAS HRAS GNAS ERBB2
12
IL-2 Pathway 63
Show member pathways
 13.33 TP53 MAP2K2 KRAS HRAS GNAS ERBB2
13
TNFR1 Pathway 63
Show member pathways
 13.22 VEGFA TP53 PIK3CA MAP2K2 KRAS HRAS
14
DAG and IP3 signaling 65
Show member pathways
 13.19 SMAD4 RXRA KRAS HRAS GNAS EGFR
15
G-Beta Gamma Signaling 63
Show member pathways
 13.19 VEGFA MAP2K2 KRAS HRAS GNAS EGFR
16
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.19 TP53 SMAD4 RXRA PIK3CA MAP2K2 KRAS
17
Phospholipase-C Pathway 63
Show member pathways
 13.17 TP53 MAP2K2 KRAS HRAS GNAS EGFR
18
fMLP Pathway 63
Show member pathways
 13.14 VEGFA TP53 MAP2K2 KRAS HRAS GNAS
19
PI3K-Akt signaling pathway 36
Show member pathways
 13.1 VEGFA TP53 RXRA PIK3CA MAP2K2 KRAS
20
Human cytomegalovirus infection 36
Show member pathways
 13.06 VEGFA TP53 PIK3CA MAP2K2 KRAS HRAS
21
Regulation of lipid metabolism Insulin signaling-generic cascades 23
Show member pathways
 13.05 VEGFA PIK3CA MAP2K2 KRAS HRAS ERBB2
22
Aldosterone synthesis and secretion 36
Show member pathways
 13.05 MAP2K2 KRAS HRAS GNAS EGFR CTNNB1
23
Focal Adhesion 36 1
Show member pathways
 13.05 VEGFA PIK3CA MAP2K2 KRAS HRAS ERBB2
24
NFAT and Cardiac Hypertrophy 63
Show member pathways
 13.02 PIK3CA MAP2K2 KRAS HRAS GNAS ERBB2
25
Development Angiotensin activation of ERK 23
Show member pathways
 12.95 PIK3CA MAP2K2 KRAS HRAS EGFR
26
MAPK signaling pathway 36 1
12.92 VEGFA TP53 MAP2K2 KRAS HRAS ERBB2
27
Beta-Adrenergic Signaling 63
Show member pathways
 12.9 MAP2K2 KRAS HRAS GNAS CTNNB1
28
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.88 TP53 PIK3CA KRAS HRAS ERBB2 EGFR
29
Ras signaling pathway 36
Show member pathways
 12.88 VEGFA PIK3CA MAP2K2 KRAS HRAS GNAS
30
Development HGF signaling pathway 23
Show member pathways
 12.87 TP53 PIK3CA MAP2K2 KRAS HRAS ERBB2
31
Apoptosis Modulation and Signaling 1
Show member pathways
 12.86 TP53 PIK3CA MAP2K2 KRAS HRAS CDKN2A
32
Relaxin signaling pathway 36
Show member pathways
 12.83 VEGFA PIK3CA MAP2K2 KRAS HRAS GNAS
33
G-AlphaQ Signaling 63
Show member pathways
 12.79 MAP2K2 KRAS HRAS GNAS EGFR
34
4-1BB Pathway 63
Show member pathways
 12.79 TP53 MAP2K2 KRAS HRAS EGFR
35
Development Endothelin-1/EDNRA signaling 23
Show member pathways
 12.79 PIK3CA MAP2K2 KRAS HRAS GNAS EGFR
36
Regulation of actin cytoskeleton 36 1
12.76 PIK3CA MAP2K2 KRAS HRAS EGFR
37
ErbB signaling pathway 36 1
Show member pathways
 12.76 VEGFA TP53 PIK3CA MAP2K2 KRAS HRAS
38
Immune response IL-23 signaling pathway 23
Show member pathways
 12.75 TP53 PIK3CA KRAS HRAS ERBB2 EGFR
39
T cell receptor signaling pathway 36
Show member pathways
 12.73 PIK3CA MAP2K2 KRAS HRAS EGFR
40
Immune response Fc epsilon RI pathway 23
Show member pathways
 12.71 VEGFA PIK3CA MAP2K2 KRAS HRAS
41
Development Dopamine D2 receptor transactivation of EGFR 23
Show member pathways
 12.7 PIK3CA MAP2K2 HRAS GNAS EGFR
42
MicroRNAs in cancer 36
12.68 VEGFA TP53 PIK3CA MAP2K2 KRAS HRAS
43
mTOR signaling pathway (KEGG) 36
Show member pathways
 12.66 TP53 PIK3CA MAP2K2 KRAS HRAS ERBB2
44
Glioma 36
Show member pathways
 12.66 TP53 RXRA PIK3CA MAP2K2 KRAS HRAS
45
Oxytocin signaling pathway 36
Show member pathways
 12.63 MAP2K2 KRAS HRAS GNAS EGFR
46
VEGF Signaling 66
Show member pathways
 12.63 VEGFA TP53 SMAD4 PIK3CA MAP2K2 KRAS
47
Prolactin Signaling Pathway 1 36
Show member pathways
 12.62 PIK3CA MAP2K2 KRAS HRAS ERBB2
48
Gastric cancer 36
Show member pathways
 12.6 TP53 SMAD4 RXRA PIK3CA MAP2K2 KRAS
49
Apoptosis Pathway 70
Show member pathways
 12.59 TP53 PIK3CA MAP2K2 KRAS HRAS ERBB2
50
VEGF Pathway (Qiagen) 63
Show member pathways
 12.57 VEGFA PIK3CA MAP2K2 KRAS HRAS EGFR
Sources

GO Terms for Pancreatic Adenocarcinoma

About this section

Cellular components related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.03 VEGFA TP53 SMAD4 RXRA PIK3CA MYCNOS
2 nucleoplasm GO:0005654 10 U2AF1 TP53 SMAD4 SF3B2 RXRA POLE
3 nucleus GO:0005634 9.53 U2AF1 TP53 SMAD4 SF3B2 RXRA POLE
4 perinuclear region of cytoplasm GO:0048471 9.5 PIK3CA MAP2K2 HRAS GNAS ERBB2 EGFR

Biological processes related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 10.21 VEGFA TP53 SMAD4 RXRA MED12 ERBB2
2 negative regulation of cell proliferation GO:0008285 10.02 TP53 SMAD4 HRAS CTNNB1 CDKN2A
3 negative regulation of gene expression GO:0010629 9.96 VEGFA TP53 MAP2K2 HRAS CTNNB1
4 positive regulation of cell proliferation GO:0008284 9.95 VEGFA MYCNOS KRAS HRAS ERBB2 EGFR
5 heart development GO:0007507 9.93 TP53 MED12 ERBB2 CTNNB1
6 in utero embryonic development GO:0001701 9.93 VEGFA TP53 SMAD4 CTNNB1
7 MAPK cascade GO:0000165 9.93 MAP2K2 KRAS HRAS ERBB2 EGFR
8 positive regulation of transcription by RNA polymerase II GO:0045944 9.91 VEGFA TP53 SMAD4 RXRA MED12 HRAS
9 positive regulation of protein kinase B signaling GO:0051897 9.9 VEGFA PIK3CA ERBB2 EGFR
10 positive regulation of protein phosphorylation GO:0001934 9.88 VEGFA KRAS HRAS ERBB2 EGFR
11 positive regulation of gene expression GO:0010628 9.87 VEGFA TP53 KRAS HRAS ERBB2 CTNNB1
12 positive regulation of MAPK cascade GO:0043410 9.85 VEGFA HRAS ERBB2 CTNNB1
13 liver development GO:0001889 9.8 PIK3CA KRAS HRAS EGFR
14 cellular response to growth factor stimulus GO:0071363 9.79 ERBB2 EGFR CTNNB1
15 Ras protein signal transduction GO:0007265 9.76 TP53 KRAS HRAS CDKN2A
16 positive regulation of epithelial cell proliferation GO:0050679 9.73 VEGFA HRAS ERBB2 EGFR
17 ERBB2 signaling pathway GO:0038128 9.7 PIK3CA ERBB2 EGFR
18 cell aging GO:0007569 9.69 TP53 HRAS BRCA2
19 response to isolation stress GO:0035900 9.61 KRAS HRAS
20 positive regulation of transcription, DNA-templated GO:0045893 9.61 TP53 SMAD4 RXRA MED12 MAP2K2 EGFR
21 negative regulation of ERBB signaling pathway GO:1901185 9.59 ERBB2 EGFR
22 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.58 VEGFA TP53
23 hair follicle placode formation GO:0060789 9.58 GNAS CTNNB1
24 negative regulation of immature T cell proliferation in thymus GO:0033088 9.57 ERBB2 CDKN2A
25 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.54 TP53 MAP2K2 EGFR
26 embryonic organ development GO:0048568 9.46 TP53 POLE MED12 CTNNB1
27 positive regulation of MAP kinase activity GO:0043406 9.02 VEGFA KRAS HRAS ERBB2 EGFR

Molecular functions related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 10.03 POLE PIK3CA MAP2K2 KRAS HRAS GNAS
2 identical protein binding GO:0042802 9.97 VEGFA TP53 SMAD4 RXRA KRAS ERBB2
3 chromatin binding GO:0003682 9.63 TP53 SMAD4 POLE MED12 EGFR CTNNB1
4 RNA polymerase II transcription factor binding GO:0001085 9.5 TP53 SMAD4 CTNNB1
5 disordered domain specific binding GO:0097718 9.43 TP53 CTNNB1 CDKN2A
6 MDM2/MDM4 family protein binding GO:0097371 9.4 TP53 CDKN2A
7 protein phosphatase binding GO:0019903 9.26 TP53 ERBB2 EGFR CTNNB1
8 protein C-terminus binding GO:0008022 9.02 MED12 HRAS ERBB2 CTNNB1 BRCA2
Sources

Sources for Pancreatic Adenocarcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....